AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
P3 Health Partners Reports Q2 2025 Results with $355.8 Million Revenue, 6% YoY Drop, and $120-$170 Million EBITDA Opportunities for 2026.
ByAinvest
Friday, Aug 15, 2025 6:04 pm ET1min read
P3 Health Partners reported a 6% YoY decrease in total revenue to $355.8 million for Q2 2025, due to a 9% decline in average at-risk membership. Despite this, the company identifies $120-$170 million in EBITDA opportunities for 2026 and expects sustained profitability. Medical cost trends remained flat amidst industry-wide inflation, and the company has revised its fiscal 2025 guidance to reflect these adjustments.
P3 Health Partners Inc. (NASDAQ: PIII) reported a 6% year-over-year (YoY) decrease in total revenue to $355.8 million for Q2 2025, primarily due to a 9% decline in average at-risk membership. The company's medical margin, calculated as capitation revenue minus medical costs, stood at $30.6 million, a 25.5% decrease from the previous year. Despite these challenges, P3 Health Partners identified $120-$170 million in EBITDA improvement opportunities for 2026 and expects sustained profitability.The company's adjusted EBITDA loss deepened to $17.1 million, largely due to a single underperforming market/payer. Operating expenses declined by $3 million compared to the prior year, a 13% improvement. P3 Health Partners ended the quarter with $39 million in cash and restricted cash, reflecting strong liquidity.
P3 Health Partners' CEO, Aric Coffman, highlighted the company's progress in renegotiating contracts, which contributed approximately $5 million in Q2 and is expected to bring further benefits in the second half of the year. The company also reported a 10% YoY improvement in funding across its membership on a normalized per member basis.
Looking ahead, P3 Health Partners expects at-risk membership to remain within 109,000 to 119,000 and total revenues to fall between $1.35 billion and $1.5 billion for fiscal 2025. Medical margin is forecast between $124 million and $154 million, while adjusted EBITDA is projected to show a loss in the range of $69 million to $39 million.
The company's liquidity remains a watch point, with $39.3 million in cash and restricted cash as of June 30, 2025, and sustained operating cash outflows. P3 Health Partners does not currently pay a dividend.
References:
[1] https://finance.yahoo.com/news/p3-health-partners-inc-piii-190448868.html
[2] https://www.nasdaq.com/articles/p3-health-partners-posts-q2-revenue-drop
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet